Why the study?
Does rivaroxaban reduce the risk of a recurrent event in patients with venous thromboembolism in equipoise for continued anticoagulation compared to aspirin?
Does rivaroxaban reduce the risk of a recurrent event in patients with venous thromboembolism in equipoise for continued anticoagulation compared to aspirin?
Rivaroxaban at either 10 mg or 20 mg doses is superior to aspirin for preventing recurrent venous thromboembolism during extended treatment, without significantly increasing bleeding risk.
Supports rivaroxaban over aspirin for extended VTE therapy; confirms reduced recurrence without excess bleeding in equipoise patients.
Among patients with venous thromboembolism in equipoise for continued anticoagulation, the risk of a recurrent event was significantly lower with rivaroxaban at either a treatment dose (20 mg) or a prophylactic dose (10 mg) than with aspirin, without a significant increase in bleeding rates. (Funded by Bayer Pharmaceuticals; EINSTEIN CHOICE ClinicalTrials.gov number, NCT02064439 .).
No takes yet. Share an insight, caveat, or question.
Weitz et al. (2017) studied this question.